(Q38164821)

30 August 2017

title

The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma (English)

1 reference

30 August 2017

9

Ola Landgren

1 reference

30 August 2017

3

Adriana Zingone

1 reference

30 August 2017

Elisabet E Manasanch

1

1 reference

30 August 2017

Neha Korde

2

1 reference

30 August 2017

Nishant Tageja

4

1 reference

30 August 2017

Carlos Fernandez de Larrea

5

1 reference

30 August 2017

Manisha Bhutani

6

1 reference

30 August 2017

Peter Wu

7

1 reference

30 August 2017

Mark Roschewski

8

1 reference

30 August 2017

publication date

24 January 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

55

1 reference

30 August 2017

issue

8

1 reference

30 August 2017

page(s)

1707-1714

1 reference

A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Resolution of the ATP-dependent proteolytic system from reticulocytes: a component that interacts with ATP

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

A ubiquitin stress response induces altered proteasome composition.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Ubiquitin depletion as a key mediator of toxicity by translational inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Inhibition of proteasome deubiquitinating activity as a new cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Molecular cloning, sequence, and tissue distribution of the human ubiquitin-activating enzyme E1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Assembly and function of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

A cryptic protease couples deubiquitination and degradation by the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Protein degradation by the ubiquitin-proteasome pathway in normal and disease states

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Some assembly required: dedicated chaperones in eukaryotic proteasome biogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

20S proteasome assembly is orchestrated by two distinct pairs of chaperones in yeast and in mammals.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

A heterodimeric complex that promotes the assembly of mammalian 20S proteasomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Ump1p is required for proper maturation of the 20S proteasome and becomes its substrate upon completion of the assembly.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Multiple assembly chaperones govern biogenesis of the proteasome regulatory particle base

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Dissection of the assembly pathway of the proteasome lid in Saccharomyces cerevisiae

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

A third interferon-gamma-induced subunit exchange in the 20S proteasome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Regulation of CD8+ T cell development by thymus-specific proteasomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Proteasomes in immune cells: more than peptide producers?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Progressively impaired proteasomal capacity during terminal plasma cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

CHOP-independent apoptosis and pathway-selective induction of the UPR in developing plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Aggresomes, inclusion bodies and protein aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Characterization and dynamics of aggresome formation by a cytosolic GFP-chimera

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Autophagy-mediated clearance of aggresomes is not a universal phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Autophagy: from phenomenology to molecular understanding in less than a decade

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Cytoplasmic components in hepatic cell lysosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Effect of autophagy on multiple myeloma cell viability

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Control of autophagic cell death by caspase-10 in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

PERK mediates cell-cycle exit during the mammalian unfolded protein response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

NF-kappa B as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Membrane biogenesis during B cell differentiation: most endoplasmic reticulum proteins are expressed coordinately

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Sequential waves of functionally related proteins are expressed when B cells prepare for antibody secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Proteasome inhibitors: an expanding army attacking a unique target

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Autophagy counteracts apoptosis in human multiple myeloma cells exposed to oridonin in vitro via regulating intracellular ROS and SIRT1

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

High plasma proteasome levels are detected in patients with metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Heightened levels of circulating 20S proteasome in critically ill patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Serum 20S proteasome is elevated in patients with renal cell carcinoma and associated with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

Sequential interaction of the chaperones BiP and GRP94 with immunoglobulin chains in the endoplasmic reticulum

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.828351

10.3109/10428194.2013.828351

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference